morphine sulfate · Ohemo Life · NDA 206544
Morphabond Er
Earliest generic entry, as listed · earliest of 4 marketed strengths
12 Aug 2028
No marketed reference-listed strength; date taken from all listed strengths.
Blocked by patent: US 10314788, US 7955619.
Listed patents · 2 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 10314788 | drug product · sets the listed date | 12 Aug 2028 |
| US 7955619 | drug product · sets the listed date | 12 Aug 2028 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 4
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 206544 · 001 · RLD · discontinued | tablet, extended release, oral | 15MG | 12 Aug 2028 |
| 206544 · 002 · RLD · discontinued | tablet, extended release, oral | 30MG | 12 Aug 2028 |
| 206544 · 003 · RLD · discontinued | tablet, extended release, oral | 60MG | 12 Aug 2028 |
| 206544 · 004 · RLD · discontinued | tablet, extended release, oral | 100MG | 12 Aug 2028 |